← Browse by Condition

Medical Condition

lymphoma

Total Trials

31

Recruiting Now

31

Trial Phases

Phase 2, Phase 3, Phase 2, Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — lymphoma Clinical Trials

How many clinical trials are currently recruiting for lymphoma?

ClinicalMetric currently tracks 31 actively recruiting clinical trials for lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 31. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for lymphoma?

lymphoma research spans Phase 1 (6 trials), Phase 2 (12 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a lymphoma clinical trial?

Eligibility criteria for lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

6

Phase 2

12

Phase 3

3

Top Sponsors

Institute of Hematology & Blood Diseases Hospital, China 2 trials

National Cancer Institute (NCI) 2 trials

Cancer Research UK 1 trial

Insel Gruppe AG, University Hospital Bern 1 trial

Liling Zhang 1 trial

Recruiting Clinical Trials

NCT05770037 Phase 2, Phase 3

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Cancer Research UK

NCT06430736 Phase 2

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

Insel Gruppe AG, University Ho...

NCT06867536 Phase 2

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

NCT07082803 Phase 1

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

United States, Austr...

Treeline Biosciences, Inc.

Registry of Older Patients With Cancer

UNC Lineberger Comprehensive C...

NCT05921253 EARLY_Phase 1

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

University of Oklahoma

NCT05156203 Phase 1

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Taivex Therapeutics Corporatio...

NCT03823534 Phase 3

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

St. Louis University

National Longitudinal Cohort of Hematological Diseases

Institute of Hematology & Bloo...

NCT06510309 Phase 2

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Gottfried von Keudell, MD PhD

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

University of Nebraska

Pediatric PET/MR Image Registry

Stanford University

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Massachusetts General Hospital

NCT05294055 Phase 2

Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Institute of Hematology & Bloo...

Whole Body MRI in Oncology

Istituto Romagnolo per lo Stud...

AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)

Belgium, France

Erasme University Hospital

NCT06563596 Phase 2

Epco, Zanu, Ritux for R/R FL or MZL

Reid Merryman, MD

AI-assisted Diagnosis of Malignant Brain Tumors

Second Affiliated Hospital, Zh...

Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients

Haikou Affiliated Hospital of ...

NCT06826118 Phase 2

Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

The First Affiliated Hospital ...

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

M.D. Anderson Cancer Center

NCT02332668 Phase 1, Phase 2

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

United States, Brazi...

Merck Sharp & Dohme LLC

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

Denmark, France, Ger...

Fundación Centro Nacional de I...

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

NCT03223610 Phase 1, Phase 2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Cancer Institute (NCI...

NCT05389293 Phase 2

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Memorial Sloan Kettering Cance...

NCT05006482 Phase 3

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

University of Rochester

Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)

IRCCS Azienda Ospedaliero-Univ...

Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes

Peking University Third Hospit...

NCT03258567 Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

National Cancer Institute (NCI...

NCT06343311 Phase 1, Phase 2

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Estrella Immunopharma, Inc.

Related Conditions

multiple myeloma (7) leukemia (6) follicular lymphoma (3) non hodgkin lymphoma (3) lymphoma non hodgkin (2) lymphoproliferative disorder (2) acute myeloid leukemia (2) myelodysplastic syndrome (2) marginal zone lymphoma (2) refractory lymphoma (2) haematological malignancy (1) malignant neoplasm (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology